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Many viral and bacterial pathogens establish infections through mucosal surfaces in their initial stage. However, only a few
nonreplicating molecules successfully induce strong mucosal immune reaction without the addition of adjuvants by oral
administration. To overcome this difficulty, we investigated whether hepatitis E virus-like particles (HEV-VLPs) could be
utilized as a carrier molecule for foreign antigenic epitopes and to stimulate mucosal immunity without the need for
adjuvants. To accomplish this goal, we incorporated a B cell epitope tag, consisting of 11 amino acids at the C-terminal of
HEV-VLP. The chimeric VLP showed morphology similar to that of the mature HEV virion and VLP. The inserted epitope was
reactive with a specific monoclonal antibody in the VLP form, suggesting that it was exposed on the surface of the VLP. After
oral administration without adjuvant, this chimeric HEV induced significant levels of specific IgG and IgA to both the inserted
epitope and HEV-VLP in intestinal secretions. These humoral immune responses were observed as early as 2 weeks after
the first immunization. These results suggest the potential of HEV-VLP as a mucosal vaccine carrier vehicle for thetion. ©
virus; vINTRODUCTION
Hepatitis E virus (HEV) is a calicivirus-like, unclassi-
fied positive-strand RNA virus that causes acute hepati-
tis in humans by fecal–oral transmission (Berke and
Matson, 2000; Reyes et al., 1999; Wong et al., 1980).
Though no in vitro culture system to amplify HEV has
been developed, overexpression of a part of open read-
ing frame 2 (ORF2) in the baculovirus expression system
allows this protein to assemble into virus-like particles
(VLPs) (Li et al., 1997b). Formation of this VLP occurs only
when the N-terminal of ORF2, where the potential signal
sequence is encoded, was deleted from the expression
construct (Li et al., 1997b; Tam et al., 1991). Further, it was
reported that an additional endogenous cleavage of 52
amino acids at the C-terminal was necessary for the
assembly of VLP (Li et al., 1997b; Xing et al., 1999; T. C.
Li, unpublished data). HEV-VLP appears as an empty
particle that is slightly smaller than the mature HEV
particle (Li et al., 1997b; Xing et al., 1999). Recently, it was
found that the VLP elicits strong immune responses
1 To whom correspondence and reprint requests should be ad-
dressed at Department of Bioregulation, Mie University School of Med-273when administered orally or intraperitoneally into mice
(Li et al., 2001).
Many pathogenic viruses and bacteria establish their
initial infections through mucosal surfaces. Conse-
quently, vaccine strategies that can stimulate mucosal
immunity have been widely studied (Bergmann and
Waldman, 1988; Ulrich et al., 1998). Recent research
demonstrated that mucosal immunity involves a sys-
temic network of mucus throughout a body and plays a
crucial part of the defense mechanisms against infection
(Boyaka et al., 1999; Czerkinsky et al., 1999).
Stimulation of mucosal immunity through oral admin-
istration of vaccines is beneficial in terms of its conve-
nience (Morrow et al., 1999). However, oral immunization
with nonreplicating molecules faces several difficulties,
including the low pH in the stomach, proteolytic enzymes
in the digestive tract, and physical as well as biochem-
ical barriers associated with the mucosal surface itself
(Morrow et al., 1999). Once these barriers are overcome,
oral immunization by nonreplicating molecules can stim-
ulate mucosal immunity through the specialized epithe-
lial M cells and the intestinal lymphoid organs (Neutra,
1999). It is believed that the particulate form itself and the
affinity for the mucosal surface mediate the antigenicity
of immunogens in the case of oral administration (Berg-presentation of antigenic epitopes through oral administra
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mechanisms and critical parameters are yet to be eluci-
dated.
Mucosal immunization with VLPs is a relatively new
approach for vaccine development among nonreplicat-
ing molecules (Medina and Guzman, 2000). The advan-
tages of VLPs as epitope carriers include the following:
(1) multiple repetitive structures of identical subunits
augment the antigenicity of the inserted epitopes, (2) the
presence of helper T-cell (Th) epitopes on VLP molecules
provides stronger immunogenicity, (3) VLPs may stimu-
late cytotoxic T-cell responses as well as humoral im-
mune responses, and (4) specific binding to the mucosal
surface is expected, by choosing an appropriate VLP
(Allsopp et al., 1996; Ulrich et al., 1998). Oral administra-
tion of VLPs usually results in a weaker immune re-
sponse than can be achieved through nasal administra-
tion (Sedlik et al., 1999). Therefore, for oral immunization,
it is often necessary to add mucosal adjuvants, such as
cholera toxin, to the VLPs in order to induce significant
mucosal immunity (Balmelli et al., 1998; Brennan et al.,
1999; Fooks et al., 1998; Modelska et al., 1998; Mrsny et
al., 1999; O’Neal et al., 1997; Yuan et al., 1998). However,
these adjuvants can cause severe side effects (Boyaka
et al., 1999). Ideally VLPs should stimulate good immune
responses without the need for adjuvant. A VLP of Nor-
walk virus, a calicivirus, is one of the few successful oral
mucosal vaccines that do not require an adjuvant (Ball et
al., 1998, 1999). Although the Norwalk virus-VLP showed
encouraging results for induction of Norwalk virus-spe-
cific antibody in phase 1 trials, a chimeric VLP has not
yet been reported. Successful oral mucosal vaccination
without an adjuvant has also been reported using a
chimeric plant virus particle carrying two rabies virus
epitopes (Modelska et al., 1998). This chimeric virus is,
however, replication-competent in plants and may be
more difficult than nonreplicating VLPs in control of leak-
age to the environment.
In the present study, we investigated the potential of
an HEV-VLP as an oral vaccine vehicle that presents
foreign immunogenic epitopes and stimulates mucosal
immunity without the addition of any kind of adjuvant.
Since an HEV-VLP could induce immune responses by
the oral route (Li et al., 2001), it was highly probable that
the chimeric HEV-VLP could induce immune response to
inserted foreign epitopes as well. We report that an
HEV-VLP can accommodate at least a B cell epitope
consisting of 11 amino acids and elicit significant levels
of specific antibody to the inserted epitope in intestinal
fluids.
RESULTS
Formation of chimeric VLP containing a foreign
epitope
To investigate whether HEV-VLP can accommodate an
antigenic epitope, we examined six insertion sites, in-
cluding four internal positions and both the N- and the
C-termini of dORF2. Utilizing any of the insertion sites,
the chimeric dORF2 was expressed at almost equal
levels in the cell lysates (Fig. 1A). The antigenicity of the
tag epitope was maintained in all cases, as evidenced by
Western blot analysis (Fig. 1B). Even at the C-terminal,
where the native HEV amino acid sequence is cleaved,
the tag was not cleaved off from dORF2 (Fig. 1B, lane C).
Among these chimeras, only the N- and C-terminal in-
sertions resulted in the chimeric dORF2 being released
into the culture supernatant at significant amounts (Figs.
2C and 2D), although small amounts were released
when the insertions were made at either site 3 or 4.
These results indicate that internal insertions somehow
disturbed the release of dORF2 into the culture superna-
tants.
We attempted to purify the chimeric VLP from the
supernatant of Tn5 cells expressing chimeric dORF2 with
the tag at either the C- or the N-terminus. Since the
released chimeric dORF2 with the tag insertion at either
site 3 or 4 could not be precipitated by the initial ultra-
centrifugation (data not shown), we did not make any
further attempt to use them. As shown in Fig. 2A, the
chimeric VLP with the tag at the C-terminal (VLP-52C)
was purified by ultracentrifugation through CsCl as pre-
viously described for the HEV-VLP (Li et al., 1997b). The
VLP-52C was slightly larger than the HEV-VLP without
the tag (Fig. 2A). This purified VLP-52C retained the
antigenicity of HEV as well as the intact tag epitope, as
shown by the reactivity of specific antibodies (Figs. 2B
and 2C). In contrast, the chimeric dORF2 with the tag at
the N-terminal (VLP-52N) did not form a visible band in
the CsCl gradient, although it was pelleted from the
supernatant by ultracentrifugation (data not shown).
FIG. 1. Expression of chimeric dORF2. (A) Expression in the cell
lysates was examined by Coomasie brilliant blue staining. (B) Antige-
nicity of the tag epitope in the cell lysates was confirmed by Western
blotting with the anti-tag antibody. (C) Presence of each chimeric
dORF2 in the cell supernatant (8 l) was examined by Western blotting
with the anti-tag antibody. The insertion site for each chimera is indi-
cated at the top of the panel. N, N-terminal; 1 to 4, sites 1 to 4,
respectively; C, C-terminal. Arrowhead on the right of each panel
indicates the position of the chimeric dORF2.
274 NIIKURA ET AL.
Characterization of the chimeric VLP
By electron microscopic observation, the VLP-52C was
approximately 25 nm in diameter and indistinguishable
from the VLP without the tag (Fig. 3). Utilizing two meth-
ods, we confirmed that the inserted epitope tag was
exposed on the surface. The intact VLP-52C was immu-
noprecipitated with the anti-tag antibody, while the anti-
HEV antibody immunoprecipitated both VLP-52C and the
VLP without the tag (Fig. 4). Furthermore, the anti-tag
antibody specifically reacted with the intact VLP-52C in
an enzyme-linked immunosorbent assay (ELISA) (data
not shown). These results suggested that the tag epitope
was exposed on the surface of VLP-52C.
Antibody response to VLP-52C
Mice were immunized with 50 g of purified VLP-52C
by the oral route four times at 2-week intervals. Specific
IgG antibodies to the tag, as well as to HEV, were
detected in the intestinal fluids as early as 2 weeks
postimmunization (wpi) (Fig. 5A). The IgG levels in the
intestinal fluids kept increasing until the termination of
the experiments. Specific IgA to both the tag and HEV
also appeared in the intestinal fluids from 2 wpi, paral-
leling the IgG levels (Fig. 5B). The IgA levels kept in-
creasing until termination of the experiment as well. As
expected, the control mice immunized with VLP without
the tag developed IgG and IgA only to HEV.
In sera, specific IgG antibody levels to both the tag and
HEV showed slightly higher optical density (OD) values
than the nonimmunized controls, but never reached sig-
nificant levels, as it did in intestinal fluids (Fig. 5C). The
specific IgA levels in sera were also low, although the
OD values were again higher than the nonimmunized
controls (Fig. 5D). The control mice immunized with VLP
without the tag showed low OD values similar to HEV.
FIG. 2. Purification of the chimeric VLP. Purified VLP-52C was ana-
lyzed for its purity (A) and reactivity to anti-HEV (B) and anti-tag anti-
bodies (C). (A) Equal amounts (0.3 g) of purified VLP-52C (52C) and
VLP without tag (w/o Tag) were separated on SDS–PAGE and stained
by Coomasie brilliant blue staining. Positions of molecular weight
markers are indicated on the right of the panel. (B and C) Equal
amounts (0.1 g) of VLP-52C (52C) and VLP without tag (w/o Tag)
were analyzed by Western blotting using anti-HEV (B) and anti-tag (C)
antibodies, respectively.
FIG. 3. Electron micrograph of VLP-52C. VLP-52C (A) and VLP without
the tag (B) were observed under electron microscopy after negative
staining at a magnification of 60,000. Inserted bar indicates 100 nm.
FIG. 4. Surface exposure of the tag epitope on VLP-52C. Surface
exposure of the tag epitope on intact VLP-52C was examined by
immunoprecipitation with the anti-tag antibody. Antibodies used are
indicated at the top of panel. none, negative control without antibody;
-Tag, anti-tag antibody; -HEV, anti-HEV antibody; cont., purified VLP-
52C and VLP without tag were run as controls. Second row indicates
VLP either with () or without the tag ().
FIG. 5. IgG (A and C) and IgA (B and D) levels in intestinal fluids (A
and B) and sera (C and D) of orally immunized mice. Circles and
triangles indicate HEV-specific and the tag epitope-specific antibody
levels, respectively, in individual mice. Two immunized mice were
sacrificed at each time point (2, 4, 6, and 8 weeks p.i.). Specific antibody
levels to HEV and the tag epitope of control mice immunized with VLP
without the tag (closed circles and closed triangles, respectively) and
background levels of antibody to HEV and the tag epitope of nonim-
munized mice (squares and crosses, respectively) are also shown.
Antibody levels are indicated as OD405 in ELISA when sera and intes-
tinal fluids were diluted at 1:100 and 1:2, respectively.
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The specific antibodies in the intestinal fluids were
analyzed for their isotypes at 10 wpi. At this time point,
average OD values and SD for IgG and IgA in the intes-
tinal fluids were 1.02 0.22 and 0.64 0.038, and 0.96
0.086 and 0.66  0.040, respectively, to HEV and the tag
in three mice immunized with the chimeric VLP. In the
control mice immunized with VLP without the tag, the
average OD values and SD for IgG and IgA were 0.88 
0.047 and 0.64  0.027, and 0.11  0.024 and 0.084 
0.013, respectively, to HEV and the tag. All subclasses of
IgGs except IgG3, IgM, and IgA to HEV were evident in
all mice (Fig. 6B). All mice failed to develop IgG3 to both
the tag and HEV above the detectable level (Figs. 6A and
6B). In the control mice immunized with VLP without the
tag, very similar HEV-specific antibody reactions to those
with the chimeric VLP were shown (Fig. 6B), while no
detectable level of any isotype antibody specific to the
tag was observed (Fig. 6A), as expected.
DISCUSSION
We have successfully generated chimeric VLPs based
on HEV dORF2. With electron microscopy, the chimeric
VLP was indistinguishable from the VLP without an in-
serted foreign epitope. This chimeric VLP induced anti-
bodies in the intestinal fluids to both the inserted tag
epitope and HEV-VLP. No adjuvant was required to in-
duce significant antibody levels, suggesting that this
chimeric VLP may be useful as an oral mucosal vaccine
vehicle.
The precise mechanisms involved in the HEV virion
formation are not yet clear. It was reported that intact
ORF2 is expressed as a membrane glycoprotein when
artificially expressed in mammalian cells in vitro (Jameel
et al., 1996; Zafrullah et al., 1999), most probably because
the N-terminal amino acid sequence serves as a signal
peptide. On the other hand, the intact ORF2 expression in
insect cells resulted in various sizes of proteins with
cleavages at both the N- and the C-termini; the 53-kDa
polypeptides were secreted in the culture supernatant
(McAtee et al., 1996a,b; Robinson et al., 1998). It was also
reported that only after cleavage of the C-terminal, which
resulted in molecular mass reduction to 54 kDa, ORF2
participates in the VLP formation (Li et al., 1997b; Xing et
al., 1999). The added tag 52 amino acids upstream from
the C-terminal where dORF2 was normally cleaved in
insect cells was not cleaved off in the infected cells
during the generation of the chimeric VLP. This is most
likely due to the alteration of the amino acid sequence
recognized by the proteolytic enzyme involved in the
C-terminal modification of HEV-VLP. The successful ad-
dition of extra amino acid sequences to the C-terminal of
dORF2 suggests that the presence of extra amino acids
at the C-terminal is not crucial for preventing dORF2 from
being incorporated into the VLP form. Rather, the amino
acid sequences encoded by the HEV ORF2 genome
prevented the formation of VLP.
The results of immunoprecipitation and ELISA using
intact chimeric VLPs suggest that the tag epitope is
exposed on the surface of the HEV-VLP. The successful
induction of antibodies to the tag may also support the
hypothesis that the tag is exposed on the surface, since
an internally localized B-cell epitope in chimeric parvo-
virus-VLP failed to induce a specific antibody response
(Rueda et al., 2000). Furthermore, this hypothesis is con-
sistent with the three-dimensional analysis of the Nor-
walk virus-VLP particle, in which the C-terminal is ex-
posed to the VLP surface (Prasad et al., 1999). The
instability of VLP-52N during the CsCl purification may
also be explained by the internal location of the N-
terminal in the Norwalk virus-VLP. Altered morphology
after CsCl purification was reported with a chimeric
parovirus-VLP with an epitope insertion inside of the VLP
(Rueda et al., 2000). Alternatively, it is also possible
VLP-52N might have aggregated but did not form VLP in
the supernatants. Internal insertions of the tag epitope
into dORF2 abolished the VLP formation. The insertion
sites 2, 3, and 4 were within or fairly close to the reported
antigenic region (Khudyakov et al., 1993, 1994, 1999),
though the localization of these B cell epitopes in ORF2
is somewhat controversial (Li et al., 1997a). Considering
that B-cell epitopes are generally hydrophilic and most
likely exposed to the VLP surface, B-cell epitope regions
may not be directly involved in the protein–protein inter-
actions to form the VLP. Our unsuccessful insertions into
internal sites suggest that the integrity of internal regions
must be maintained for proper protein folding and VLP
formation. To find potential internal insertion sites, a
precise three-dimensional structural map of the HEV-VLP
may be necessary.
The induction of antibody by oral administration to the
tag indicates that the tag amino acid sequence survived
the harsh conditions in the digestive tract, even though it
seemed exposed on the VLP surface. The inserted tag
epitope induced an antibody response strongly biased
for intestinal fluids. Similarly biased induction of antibod-
FIG. 6. Isotypes of antibodies specific to the tag epitope (A) and HEV
(B) in intestinal fluids in orally immunized mice sacrificed at 10 wpi. IgA
(A), IgM (M), and IgG subclass (G1, G2a, G2b, and G3) levels were
examined by ELISA using isotype-specific secondary antibodies and
shown as end-point titers. Solid and open bars indicate antibody levels
of each mouse immunized with the chimeric VLP and VLP without tag
epitope insertion, respectively.
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ies in intestinal secretion was observed by oral immuni-
zation with chimeric plant virus particles (Modelska et
al., 1998). Considering the marginal specific antibody
levels in sera, the dose (50 g) used in these experi-
ments may not have been sufficient to induce significant
serum antibody. To evaluate the potential of chimeric
HEV-VLP to induce systemic serum antibodies, further
experiments are necessary. Contrary to our observations
with the chimeric HEV-VLP, the induction of IgA response
after oral delivery required a higher concentration of
antigen than that required to induce serum IgG with
Norwalk virus-VLP (Ball et al., 1998). In addition, the
intestinal IgA response occurred later than the serum
IgG response. Even in that report, doses exceeding 200
g were necessary to induce consistent serum IgG.
Taken together, the chimeric HEV-VLP is a very strong
stimulator for mucosal immunity when administered
orally. Recent reports showed that a parvovirus-VLP
(Sedlik et al., 1999) and a papillomavirus-VLP (Liu et al.,
1998) can induce specific CTL to the inserted T cell
epitope by mucosal immunization without adjuvant. We
are now investigating whether the HEV-VLP also induces
specific CTL responses by using chimeric VLPs with CTL
epitopes instead of the tag.
The keys for successful oral stimulation of the immune
response are to increase the uptake of carrier molecules
by M cells utilizing a particulate form and to ensure
specific binding with the intestinal epithelium (Bergmann
and Waldman, 1998; de Aizpurua and Russell-Jones,
1988; Estes et al., 2000). These keys may have worked in
our experimental model as well. Recent findings showed
that HEV infects many animal species including rodents
(Favorov et al., 2000; Maneerat et al., 1996). Therefore, it
is possible that the chimeric HEV-VLP specifically bound
to the intestinal epithelium of the inoculated mice. On the
other hand, as HEV naturally infects hosts by the oral–
fecal route, it is highly possible that the VLP retained the
particulate structure in the digestive tract including the
acidic environment in the stomach. In fact, the HEV-VLP
was shown to be stable in an acidic environment (Xing et
al., 1999). These characteristics are advantageous for the
HEV-VLP to be an oral vaccine vehicle. The chimeric
HEV-VLP molecules would probably elicit similar strong
immune responses in other host species including hu-
man as well.
We have examined secretory IgA levels only in the
intestinal secretion. However, it has become apparent
that IgA responses on different mucosal surfaces were
achieved simultaneously, despite the initial stimulation of
a single mucosal site (Boyaka et al., 1999; Mestecky and
McGhee, 1987). Therefore, it is probable that oral admin-
istration of chimeric HEV-VLP stimulates IgA responses
simultaneously on distant mucosal surfaces as well. This
phenomenon significantly extends the potential use of
chimeric HEV-VLP as an oral vaccine vehicle.
MATERIALS AND METHODS
Cells, animals, and viruses
Sf9 cells were maintained in TC100 medium (Gibco
BRL, Rockville, MD) supplemented with 10% fetal bovine
serum (FBS), 5% tryptose phosphate broth (Difco, Detroit,
MI), and kanamycin. Tn5 cells were maintained in Excell
405 serum-free medium (JRH, Lenexa, KS). BALB/c mice
(4 weeks old, female) were purchased from Clea Japan
(Tokyo, Japan). Recombinant baculoviruses were plaque-
purified twice and amplified on Sf9 cells.
Antibodies
The rabbit antiserum to HEV-VLP was previously de-
scribed (Li et al., 1997b). The monoclonal antibody rec-
ognizing a B-cell tag epitope on glycoprotein D of herpes
simplex virus was purchased from Novagen (Madison,
WI). This antibody recognizes the amino acid sequence,
QPELAPEDPED.
Construction of recombinant baculoviruses
pVL5480/7126, the baculovirus transfer vector which
includes a portion of the ORF2 from HEV (dORF2), was
described previously (Li et al., 1997b). To insert the tag
sequence within dORF2, oligonucleotides that encode
the tag amino acid sequence were synthesized as
shown in Table 1. A pair of oligonucleotides was an-
nealed and end-filled with the Klenow enzyme. The filled,
double-stranded oligonucleotides were ligated into the
dORF2 that had previously been digested by a restriction
endonuclease and blunted with either the Klenow en-
zyme or T4 DNA polymerase. The restriction sites used
for insertion sites 1 to 4 were HindIII, SacII, BssHII, and
SacII sites at nucleotide positions 5679, 6245, 6664, and
6773, respectively. For each site, oligonucleotide pairs of
Htg5(0) and Htg3(GA), Htg5(1) and Htg3(0), Htg5(0) and
Htg3(GG), and Htg5(1) and Htg3(0), respectively, were
used. After the tag insertion, the chimeric dORF2 genes
were amplified by PCR using the primers HEVBacBg and
TABLE 1
Oligonucleotides Used in This Study
Oligonucleotide Sequence (5 to 3)
HEVBacBg CGCAGATCTATGGCGGTCGCTCCAGCCC
HEV52Pr CTGCAGCTATGCTAGCGCAGAGTG
Htg5 (0) CAGCCTGAACTCGCTCCAGAGGA
Htg5 (1) GCCAGCCTGAACTCGCTCCAGAGGA
Htg3 (0) ATCTTCCGGATCCTCTGGAGCGAG
Htg3 (GA) TCATCTTCCGGATCCTCTGGAGCGAG
Htg3 (GG) CCATCTTCCGGATCCTCTGGAGCGAG
Tag (52) CTGCAGCTAATCTTCGGGGTCCTCCGGGGCGAGCT-
CAGGCTGTGCTAGCGCAGAGTGG
BglTag AGATCTATGGCGCAGCCTGAACTCGCTCCAGAGGA-
TCCAGAAGATGCGGTCGCTCCAGCCCATGAC
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HEV52Pr. The amplified fragments were cloned into
pGEMT Easy (Promega, Madison, WI), double-digested
by BglII and PstI, and then inserted back into pVL1393
(Invitrogen, Groningen, The Netherlands) previously di-
gested by BamHI and PstI. To add the epitope tag amino
acid sequence at either the N- or the C-terminal of
dORF2 in pVL5480/7126, the dORF2 gene was PCR am-
plified with the primer pair BglTag and HEV52Pr or the
primer pair HEVBacBg and Tag (52), respectively (Table
1). The amplified fragments were cloned into pGEMT
Easy and then ligated to the BamHI/PstI–digested
pVL1393 as BglII/PstI fragments. The C-terminal tag was
added at a position 52 amino acids upstream from the
translational terminal. This site was chosen because the
last 52 amino acids at the C-terminal of ORF2 are
cleaved off during the formation of VLP. The nucleotide
sequences around the inserted tag were determined by
an automated sequencer (ABI, Foster City, CA) and are
schematically shown in Fig. 7. The plasmid containing
the chimeric dORF2 was cotransfected with baculovirus
DNA and the recombinant baculovirus was generated as
described previously (Li et al., 1997b).
Production and purification of VLP
The production and purification of HEV-VLP were per-
formed as described (Li et al., 1997b; Xing et al., 1999).
Briefly, Tn5 cells were infected with the recombinant
baculoviruses at a m.o.i. of 5 and cultured for 6 to 7
days. The supernatant was harvested and centrifuged at
low speed, and the recombinant baculoviruses in the
supernatant were pelleted by ultracentrifugation at
10,000 g for 30 min at 4°C. The VLP in the supernatant
was collected by a further ultracentrifugation at 100,000
g for 2 h at 4°C. The pellet containing VLP was then
resuspended in 10 mM potassium-MES buffer (pH 6.2)
and further purified on a CsCl equilibrium density gradi-
ent. The purified VLP was pelleted and resuspended in
ExCell 405. The purified VLP was kept at 4°C or frozen at
20°C. The correct VLP structural formation was con-
firmed by observing a purified preparation with an elec-
tron microscope, as described previously (Li et al.,
1997b).
SDS–PAGE, Western blotting, and
immunoprecipitation
SDS–PAGE was performed on 10% acrylamide gels
using denaturing conditions. Cell lysates were prepared
in SDS–PAGE sample buffer (50 mM Tris, pH 6.8, 2% SDS,
10% 2-mercaptoethanol, 10% glycerol). Briefly, Tn5 cells
(106 cells in a 35-mm dish) were infected and incubated
for 2 days. After the infected cells were harvested and
washed with PBS, the cells were lysed in 100 l sample
buffer. The same volume of the lysates was analyzed for
the comparison of the expression level. Protein staining
was performed in 0.25% Coomasie brilliant blue in meth-
anol:water:acetic acid (9:9:2). When the protein release
in culture supernatants was analyzed, supernatants
were mixed with equal volumes of 2 SDS–PAGE sam-
ple buffer and analyzed by Western blots. For Western
blotting, the separated proteins were transferred to nylon
membranes (Millipore, Bedford, MA) in a semidry system
(ATTO, Tokyo, Japan) by a standard method. The trans-
ferred proteins were probed with either the anti-HEV or
the anti-tag antibodies and horseradish peroxidase
(HRPO)-labeled anti-rabbit IgG (Zymed, San Francisco,
CA) or anti-mouse IgG (H  L, Zymed), respectively. The
reaction was visualized with POD substrate (Wako,
Osaka, Japan). For immunoprecipitation, the purified VLP
was biotinylated by EZ-Link reagent (Pierce, Rockford, IL)
in phosphate-buffered saline (PBS, pH 7.2) as recom-
FIG. 7. Schematic diagram and sequences around the tag epitope insertion sites in dORF2. Upper rows show nucleotide sequences and lower rows
show the corresponding amino acid sequences. Amino acid numbers relative to the full-length ORF2 are indicated next to the amino acid before the
inserted amino acids. Nucleotide numbers referring to the HEV genome are in parentheses. Inserted sequences are underlined. The tag epitope
amino acid sequence is in boldface type.
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mended by the manufacturer. The biotin-labeled VLP (1
g) was precipitated with 1 l of either the anti-HEV or
anti-tag antibodies with 10 l Protein G–Sepharose (Am-
ersham Pharmacia, Little Chalfont, CA) in PBS at 4°C.
After extensive washing with PBS, the immunoprecipi-
tates were analyzed by SDS–PAGE and visualized by
avidin–HRPO (Zymed) and POD substrate after being
blotted to nylon membranes.
Enzyme-linked immunosorbent assay
Purified VLP without tag or synthesized oligopeptides
with the tag sequence (QPELAPEDPED) were coated in
multiwell plates at a concentration of 10 or 100 g/well in
100 l PBS, respectively, overnight at 4°C followed by 30
min of blocking with nonfat milk. Test samples were
added to the wells and incubated at room temperature
(RT) for 1 h. After being washed, the reacted antibodies
were detected using the HRPO-labeled goat anti-mouse
IgG (H  L) and ABTS substrate (Roche Diagnostics,
Mannheim, Germany). To evaluate the amounts of each
Ig isotype, one of the biotin-labeled secondary antibod-
ies (see below) avidin–HRPO (Prozyme, San Leandro,
CA), and ABTS substrate were used. Secondary antibod-
ies used were anti-mouse IgG1, IgG2a, IgG2b, IgG3, IgM
(Serotec, Raleigh, NC), and IgA (CALTAG, San Francisco,
CA). The IgG and IgA antibody levels were expressed as
optical densities (OD) at dilutions of either 1:2 or 1:100 for
intestinal fluids or sera, respectively. For the analyses of
antibody isotypes, twofold serial dilutions of intestinal
fluids were made and examined in the ELISA. Each
isotype level was expressed as the reciprocal of the
highest dilution that showed OD values above cut-off
values. The cut-off values were set at the average OD 
0.1 of nonimmunized control mice at each dilution. They
were calculated for each isotype and antigen.
Immunization and preparation of intestinal secretion
Mice were orally immunized four times with 50 g of
VLP with or without the tag in 100 l of PBS at 2-week
intervals. The chimeric VLP-immunized mice were sacri-
ficed at 2, 4, 6, 8, and 10 weeks after the first immuniza-
tion and the antibody levels in the intestinal secretions
and sera were determined. Two mice were sacrificed at
2, 4, 6, and 8 wpi, respectively, and three were sacrificed
at 10 wpi. Four nonimmunized mice and five immunized
with VLP without the tag were included as controls and
sacrificed at either 8 or 10 wpi. The intestinal secretions
were collected as follows. Small intestines were re-
moved and filled with 2 ml of PBS containing 50 mM
EDTA and 1 mM PMSF and left for 10 min at RT. The
contents were then transferred to a test tube, vigorously
vortexed, and then centrifuged for 10 min at 650 g at 4°C.
The supernatant was transferred to another tube and
PMSF was added to a final concentration of 1 mM. The
solution was again mixed by vortexing and centrifuged at
13,000 g for 20 min at 4°C. The supernatant was mixed
with PMSF and sodium azide to a final concentration of
1 mM and 0.01%, respectively, and incubated for 15 min
at 4°C. FBS was added to the secretion at a final con-
centration of 5%, and the solution was centrifuged for an
additional 20 min at 13,000 g at 4°C. The supernatants
were stored as intestinal fluids along with the sera at
30°C until simultaneously analyzed.
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